Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-9378
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment ; volume:15 ; number:1 ; day:12 ; month:5 ; year:2020 ; pages:1-3 ; date:12.2020
Infectious agents and cancer ; 15, Heft 1 (12.5.2020), 1-3, 12.2020
- Creator
-
Buonaguro, Luigi
Buonaguro, Franco M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13027-020-00302-x
- URN
-
urn:nbn:de:101:1-2020071721024463478507
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Buonaguro, Luigi
- Buonaguro, Franco M.
- SpringerLink (Online service)
Other Objects (12)
Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
Drug repositioning
Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study
Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten
Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
Drug repositioning
Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study
Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten
Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
Drug repositioning
Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study